(Q34210064)

31 July 2017

1 reference

title

Chronic myeloid leukaemia. STI 571 magnifies the therapeutic dilemma (English)

1 reference

31 July 2017

1 reference

1 reference

Mughal TI

1

1 reference

31 July 2017

Goldman JM

series ordinal

2

1 reference

31 July 2017

publication date

1 March 2001

1 reference

European Journal of Cancer

31 July 2017

published in

1 reference

31 July 2017

volume

37

1 reference

31 July 2017

issue

5

1 reference

31 July 2017

page(s)

561-568

1 reference

Chronic myeloid leukaemia: a therapeutic challenge

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900454-8

7 January 2021

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900454-8

7 January 2021

The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900454-8

7 January 2021

Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900454-8

7 January 2021

The biology of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900454-8

7 January 2021

The relationship between telomere length and therapy-associated cytogenetic responses in patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900454-8

7 January 2021

A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900454-8

7 January 2021

UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900454-8

7 January 2021

Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900454-8

7 January 2021

Cost-effectiveness of interferon-alpha for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900454-8

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900454-8

7 January 2021

Tyrosine-kinase inhibition in treatment of chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900454-8

7 January 2021

Bone Marrow Transplantation for Patients with Chronic Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900454-8

7 January 2021

Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900454-8

7 January 2021

Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900454-8

7 January 2021

Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900454-8

7 January 2021

Graft-versus-leukaemia: understanding and using the alloimmune response to treat haematological malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900454-8

7 January 2021

Non-myeloablative stem cell transplants

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900454-8

7 January 2021

Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900454-8

7 January 2021

Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900454-8

7 January 2021

Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900454-8

7 January 2021

Autografting for patients with chronic myeloid leukemia--the Hammersmith experience

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900454-8

7 January 2021

Mobilization and transplantation of Philadelphia-negative peripheral-blood progenitor cells early in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900454-8

7 January 2021

10.1016/S0959-8049(00)00454-8

Identifiers

DOI

1 reference

31 July 2017

1 reference